Research programme: antibody therapeutics - Adaptive Biotechnologies
Latest Information Update: 28 May 2024
At a glance
- Originator Adaptive Biotechnologies
- Class Antibodies; Antivirals
- Mechanism of Action Virus attachment modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 May 2024 No recent reports of development identified for research development in COVID-2019-infections in USA (Parenteral)
- 28 May 2024 No recent reports of development identified for research development in COVID-2019-infections(Prevention) in USA (Parenteral)
- 02 Apr 2020 Amgen and Adaptive Biotechnologies enter into a Memorandum of Understanding agreement to discover and develop antibodies for COVID-2019 infections